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The yellow fever (YF) 17D vaccine is one of the most successful live attenuated vaccines 
available. A single immunization induces both long-lasting neutralizing antibody and 
YF-specific T cell responses. Surprisingly, the mechanism for this robust immunity has not 
been addressed. In light of several recent reports suggesting flavivirus interaction with 
dendritic cells (DCs), we investigated the mechanism of YF17D interaction with DCs and the 
importance of this interaction in generating T cell immunity. Our results show that YF17D 
can infect immature and mature human DCs. Viral entry is Ca
 
2
 
 
 
 dependent, but it is 
independent of DC-SIGN as well as multiple integrins expressed on the DC surface. Similar 
to infection of cell lines, YF infection of immature DCs is cytopathic. Although infection 
itself does not induce DC maturation in vitro, TNF-
 
 
 
–induced maturation protects DCs 
from YF-induced cytopathogenicity. Furthermore, we show that DCs infected with YF17D or 
YF17D carrying a recombinant epitope can process and present antigens for CD8
 
 
 
 T cell 
stimulation. These findings offer insight into the immunologic mechanisms associated with 
the highly capable YF17D vaccine that may guide effective vaccine design.
 
The yellow fever (YF) 17D vaccine is a live
attenuated vaccine that has been used for 
 
 
 
70
yr on more than 400 million people for vacci-
nation against YF virus with a remarkable
record of safety and efficacy (1). The vaccine
strain YF17D was generated from the WT
strain Asibi and differs from Asibi by only 32
amino acids, 12 of which are clustered in the
envelope protein (2). Viscerotropism of the
parental Asibi is markedly reduced in YF17D,
but the basis of the attenuation remains un-
known. Vaccination generates both long-lasting
neutralizing antibodies and T cell responses (3,
4). The antibody response most likely accounts
for the effectiveness of the vaccine; however, a
role for cell-mediated immunity in generating
an effective immune response has also been
suggested (4). Only recently have YF-specific
human CD8
 
 
 
 T cell responses been identified
(5), but the immunologic mechanisms associ-
ated with YF-specific CD8
 
 
 
 T cell priming
are still unknown.
Given its safety and efficacy, YF17D has
been engineered as a vaccine vector for antigens
of other flaviviruses such as dengue, Japanese
encephalitis, and West Nile viruses. Some of
these chimeric viruses are in phase II clinical
trials (6). We have recently reported that
YF17D can also be engineered to deliver
epitopes from unrelated pathogens, and it is
able to induce protective immunity against
heterologous agents (7). A better understanding
of the mechanism underlying the efficacy of T
cell priming by YF vectors would offer insight
into vaccine design.
DCs are potent APCs that play a crucial
role in regulating the adaptive immune response
(8). DCs may interact with pathogens in periph-
eral tissue via direct infection or via phagocytosis
of either infected cells or viral particles. On
exposure to inflammatory signals or certain
pathogens, DCs undergo a programmed phe-
notypic maturation program coincident with
CCR7 up-regulation and migration to the
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lymph node for engagement and activation of T cells. Re-
cent studies have demonstrated DC interaction with flavivi-
ruses. Specifically, DC-SIGN, a DC-specific C-type lectin
present most robustly on immature DCs (iDCs), mediates
entry of dengue virus into DCs (9, 10) and binding of the
hepatitis C virus envelope protein (11).
In this report, we explore the interaction of YF17D with
human DCs. We investigate the ability of YF17D to infect
DCs, the requirements for viral entry, and the cytopathic effect
of YF17D in DCs. Furthermore, we evaluate the immuno-
logic determinants of DC infection by monitoring T cell re-
sponses to endogenous and model antigens from YF17D vec-
tors. This work provides new insight into the immunologic
mechanisms associated with the highly effective YF vaccine
and may provide clues relevant to effective vaccine design.
 
RESULTS AND DISCUSSION
YF17D infects immature and mature DCs
 
To test the hypothesis that the immune response induced by
YF17D vaccination may be generated by direct infection
of DCs, we exposed both immature and mature human
monocyte-derived DCs with characteristic surface pheno-
types (Fig. S1, available at http://www.jem.org/cgi/content/
full/jem.20051352/DC1) to YF17D virus. FACS analysis
for the intracellular nonstructural protein NS1 showed
robust expression in both iDCs and mature DCs (mDCs)
infected at 2 or 20 PFU/cell (Fig. 1 A). Detection of non-
structural viral proteins not present within the virion indi-
cates productive infection. Infection was confirmed using
an antibody to nonstructural protein NS4AB (NS4; Fig. 1
B). No staining was detected when UV-inactivated virus
was used for infection. In addition, virus production in both
the iDC and mDC cultures was monitored by plaque as-
say. Results showed a 3-log increase in infectious particles
within 24 h, confirming productive infection (Fig. 1 C).
Notably, no substantial difference in infectious particle pro-
duction was seen between iDC and mDC cultures. Infec-
tion at 20 PFU/cell peaks 48 h after infection and, though
infection at 2 PFU/cell may lag behind only slightly, con-
siderable differences in the percentage of infected cells per-
sist (Fig. 1 A). Induction of antiviral cytokines during infec-
tion may account for lower infectivity at 2 PFU/cell. To
exclude antibody-mediated enhancement of infection, DCs
were generated in plasma from naive donors and, in control
experiments, blocking antibodies against the Fc receptor did
not block YF17D infection (unpublished data). These data
demonstrate that YF17D can infect and productively repli-
cate in human DCs, and infection occurs irrespective of
their maturation state.
Other cell types were not as susceptible to YF infection.
High-level virus production was not seen in T cells, B cells,
or monocyte-enriched PBMCs (Fig. 1 D). In addition, in-
fection of B cell lines (MC116, RAMOS, and Raji) did not
result in productive infection (unpublished data).
 
DC infection is Ca
 
2
 
 
 
 dependent
 
The cellular receptor involved in YF17D infection is un-
known. Recent reports have identified the receptors for the
related flaviviruses West Nile virus and dengue virus as 
 
 
 
v
 
 
 
3
and DC-SIGN, respectively (9, 10, 12). In addition, the
presence of an RGD motif in the ectodomain of the YF17D
envelope protein suggests a mechanism for interaction with
integrins (13). Both integrins and DC-SIGN require divalent
cations for structural and functional integrity. Thus, to assess
a possible requirement for divalent cations, iDCs were pre-
treated with 10 mM EDTA and exposed to YF17D for 1 h
to evaluate their role in infection. NS4AB expression at 24 h
was completely blocked by EDTA (Fig. 2 A), whereas
EDTA-treated DCs were still competent for infection with
influenza (Fig. 2 B). EGTA treatment also blocked infection,
indicating a Ca
 
2
 
 
 
-dependent mechanism (Fig. 2 A). Consis-
tent with this finding, addition of Ca
 
2
 
 
 
, but not Mg
 
2
 
 
 
, was
able to overcome the EDTA block (Fig. 2 A).
In light of this result, we tested specific integrin-blocking
antibodies, including 
 
 
 
1, 
 
 
 
3, 
 
 
 
v
 
 
 
3, 
 
 
 
5, 
 
 
 
v
 
 
 
5, and 
 
 
 
v
 
 
 
6, as
well as RGD peptides, to evaluate the role of specific inte-
grins in viral entry. Antibodies and peptides were used at
concentrations reported to be sufficient for blocking West
Nile virus (12). None of the integrin-blocking antibodies
considerably inhibited infection as monitored by NS4AB ex-
pression 24 h after infection (Fig. 2 C and not depicted).
The lack of inhibition by RGD peptides is consistent with
Figure 1. iDCs and mDCs are productively infected by YF17D. 
(A) Intracellular FACS analysis of NS1 expression (indicated by the gate 
shown) in iDCs and mDCs infected with 2 or 20 PFU/cell 48 h after infection. 
(B) Intracellular staining of NS4 expression (indicated by the gate shown) 
in iDCs infected with 2 PFU/cell. (C) Virus production by iDC and mDC cultures 
measured by plaque assay on SW13. (D) Virus production by T cell– and 
monocyte-enriched PBMC fractions compared with iDCs. Values in C and 
D represent means   SD. 
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previous reports suggesting YF17D infection is independent
of the RGD motif (12, 13). These data, however, do not
rule out the possibility that YF entry uses determinants not
blocked by these antibodies or peptides.
In addition, blocking antibodies against DC-SIGN (9)
did not inhibit YF17D infection (Fig. 2 C). Antibodies
were used at saturation conditions, and binding to DCs was
confirmed by FACS (Fig. S1). These results suggest that, in
contrast to dengue, YF17D infection of DCs is not medi-
ated by DC-SIGN. This finding is consistent with our data
showing equivalent virus production in iDCs and mDCs,
which differ substantially in DC-SIGN expression (high in
iDCs, low in mDCs; Fig. 1 C and Fig. S1), as well as a re-
cent report showing the inability of DC-SIGN to permit
infection in THP-1 cells (10). In contrast with dengue virus
envelope protein, which contains one or two N-linked gly-
cans, the envelope protein of YF17D-204 used in these ex-
periments is not glycosylated (14). Although other YF17D
substrains (YF17DD and YF17D-213) may be glycosylated,
our data indicate that DC-SIGN interaction is not necessary
for infection and that YF17D interacts with DCs via mech-
anisms distinct from related flaviviruses. Although YF17D
infection of DCs is Ca
 
2
 
 
 
 dependent, the receptor for YF17D
remains elusive.
 
YF17D infection does not alter DC maturation in vitro
 
Several studies indicate that viral infection of DCs promotes
or inhibits maturation (15–17). To evaluate DC maturation
as a result of YF17D infection, surface expression levels of
CD83, CD86, and MHC class II were assayed 36 h after in-
fection. Interestingly, infection alone did not induce robust
DC maturation. Although slight up-regulation of CD86 and
MHC class II was observed (unpublished data), conventional
maturation markers such as CD83 were not expressed (Fig. 3
A). However, in contrast to inhibition of maturation by sev-
eral infectious pathogens (16, 17), YF17D infection did not
inhibit TNF-
 
 
 
–mediated DC maturation (Fig. 3 B). These
results suggest, therefore, that in the context of YF17D vac-
cination, release of inflammatory cytokines in peripheral tis-
sue may play an important role in triggering DC maturation.
This will allow for DC migration to the lymph node and
subsequent T cell engagement and priming. Consistent with
this model, an increase in TNF-
 
 
 
 has been detected in sub-
jects vaccinated with YF17D (18).
Figure 2. YF17D Infection of DCs is Ca2  dependent. (A) YF17D 
infection of iDCs at 2 PFU/cell was monitored by intracellular FACS for YF 
NS4 24 h after infection. DCs were treated as indicated with 10 mM EDTA 
or EGTA. 6 mM Ca2  or Mg2  was added as indicated. The percentage of 
NS4-positive cells is indicated. (B) Intracellular YF NS4 or surface influenza 
hemagglutinin staining after 24 or 8 h, respectively. Infection was done 
with or without pretreatment with EDTA as indicated. (C) Bar graph represents 
the percentage of iDCs staining positive for YF17D NS4 24 h after infection. 
Samples preincubated with 10  g/ml DC-SIGN or  v 3 blocking antibodies 
or 100  g/ml RGD peptides are indicated. Values represent means   SD. 
Figure 3. YF17D infection does not induce or inhibit DC maturation. 
(A) iDCs infected with 10 PFU/cell were analyzed for CD83 surface expression. 
CD83 expression of the YF17D-infected population (compared with mock 
infected) was analyzed 36 h after infection. (B) iDCs were infected with 10 
PFU/cell and exposed to TNF- /PGE-2 maturation cocktail. CD83 expression of 
the YF-infected population (compared with mock infected) was analyzed 
after 36 h. 
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Maturation protects DCs from YF17D-induced apoptosis
 
Because YF17D has been shown to be cytopathic in mam-
malian cells, we evaluated potential cytopathogenicity in hu-
man DCs using a FACS-based assay for monitoring apop-
totic cell death. Similar to infection by several other viruses,
YF17D induces cleavage of caspase-3 in iDCs and triggers
cell death. In a dataset representative of three individual ex-
periments, we show 37% (2 PFU/cell) and 54% (10 PFU/
cell) CaspaTag-positive iDCs at 48 h after infection (Fig. 4
A). These values were similar to the ones obtained in the
SW13 cell line (29% at 2 PFU/cell and 69% at 10 PFU/cell).
Interestingly, when we exposed infected iDCs to inflamma-
tory stimuli capable of inducing maturation, there was a
considerable reduction in the YF17D-induced cytopathoge-
nicity: 9% (2 PFU/cell) and 13% (10 PFU/cell) of the total
cells had activated caspase-3 48 h after infection (Fig. 4 A).
To confirm that iDC cytopathogenicity was YF17D
specific and that CaspaTag-negative mDCs were indeed
YF17D infected, we stained the infected iDCs for CD83,
YF NS4AB, and activated caspase-3. Again, in a repre-
sentative dataset, gating on the YF-infected CD83
 
 
 
 cells
showed 21% caspase activation compared with 6% in the
YF17D-negative population (Fig. 4 B). In contrast, ma-
ture YF17D-infected DCs (CD83
 
 
 
/NS4
 
 
 
) showed only
3% caspase activation (Fig. 4 B). Plaque assays performed
on the supernatants from both cultures confirmed compa-
rable levels of virus production (unpublished data). Based
on this data, we conclude that the resistance to YF17D-
induced cytopathogenicity is dependent on DC matura-
tion. This resistance to cytopathogenicity could play an
important role in allowing infected DCs to remain alive,
permitting trafficking to lymph node and priming of T cell
responses. This finding is consistent with data from the
influenza model in which DC maturation confers resis-
tance to cytopathogenicity, thereby facilitating T cell prim-
ing (15).
Figure 4. Maturation protects iDCs from YF cytopathogenicity. 
(A) Caspase activation is measured using CaspaTag–FITC in SW13, iDCs, or 
iDCs   TNF- , exposed to the indicated PFU of YF17D virus at 48 h. Tables 
indicate the percentage of cells that were CaspaTag positive. (B) YF17D-
infected iDCs or iDCs   TNF-  were identified by intracellular staining 
with NS4. CD83 staining was used to distinguish iDCs versus mDCs. Caspase 
activation of the indicated cell populations is indicated by histograms, and 
the percentage that is CaspaTag positive is indicated.
Figure 5. YF17D infection of DCs allows for processing and pre-
sentation of endogenous and model T cell epitopes. (A) DCs infected 
with influenza or YF17D were used to stimulate purified CD8  T cells from 
YF17D-immunized donor 1 or a naive donor. Stimulation was measured 
using IFN-  ELISPOT, and data are shown as spot-forming cells/106 cells. 
(B) Schematic showing the insertion site of the M1 epitope at the 2B-3 
junction. (C) DCs infected with influenza, YF17D, YF17D-M1, or pulsed 
with 10  M M1 peptide were used to stimulate CD8  T cells from a naive 
donor. T cell stimulation was measured by IFN-  ELISPOT, as mentioned in 
Materials and methods. Values represent means   SD. 
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Infection of DCs allows for processing and presentation 
of endogenous and model antigens
 
In light of the direct infection of DCs and the resistance to
YF17D-induced cell death on maturation, we evaluated the
ability of mDCs to process and present endogenous antigens
produced by YF17D. mDCs generated from subjects vacci-
nated with YF17D were infected and used to stimulate au-
tologous CD8
 
 
 
 and CD4
 
 
 
 T cells. IFN-
 
 
 
 ELISPOT results
showed that infected DCs were able to process and present
YF17D antigen for antigen-specific CD8
 
 
 
 and CD4
 
 
 
 T cell
stimulation (Fig. 5 A). Although the mechanism of process-
ing and presentation of endogenous CD4 epitopes remains
poorly characterized, antigen may be derived from the exog-
enous capture of the small percentage of dying infected cells
or by alternative mechanisms of processing (19). No T cell
response was detected in naive donors. Influenza was used as
a positive control to show T cell responses in both immune
and naive donors.
Because of the efficacy of the YF17D vaccine, many
groups have proposed its use as a vaccine vector for generat-
ing CD8
 
 
 
 T cell immunity. We propose that these vectors
may directly infect DCs, allowing for processing and presen-
tation of CD8
 
 
 
 T cell epitopes. We tested this hypothesis by
constructing a YF17D vector carrying the immunodominant
HLA-A2 M1 CTL epitope from influenza matrix protein.
The M1 CTL epitope was inserted between NS2B and NS3
proteins. This site has been shown previously to tolerate a
small insertion of foreign sequences (20). mDCs from naive
donors were infected with YF17D or chimeric YF17D-M1
virus at 2 PFU/cell as described in Materials and methods
and used to stimulate autologous CD8
 
 
 
 T cells. IFN-
 
 
 
ELISPOT results showed that YF17D-M1–infected DCs
stimulate robust M1-specific CD8
 
 
 
 T cell responses similar
to M1 peptide–pulsed or influenza-infected DCs (Fig. 5 C),
whereas DCs infected with YF17D alone did not stimulate
IFN-
 
 
 
 secretion in the naive donor. Importantly, this is the
first demonstration of a YF17D 2B/3 chimeric virus present-
ing an HLA A2 CTL epitope for T cell stimulation, and it
offers proof of principle for a possible vaccine approach.
These data indicate that the YF17D vector is capable of
delivering endogenous and recombinant epitopes to the sur-
face of the DC enabling specific T cell activation. In the
presence of a maturation stimulus produced in infected tis-
sue, we therefore propose that Ca
 
2
 
 
 
-dependent direct infec-
tion of DCs may offer a mechanism for the robust and long-
lasting immunity associated with the YF17D vaccine.
 
MATERIALS AND METHODS
 
Isolation and preparation of cells.
 
PBMCs, DCs, and T cells were pre-
pared as previously described (21). PBMCs were isolated from whole blood
by sedimentation over a Ficoll-Hypaque gradient (GE Healthcare). T cell–
enriched and T cell–depleted fractions were prepared by adherence to plas-
tic in 1% single donor plasma. iDCs were prepared from the T cell–depleted
fraction by culturing cells in the presence of 1,000 U/ml GM-CSF (Berlex)
and 500–1,000 U/ml IL-4 (R&D Systems) for 6 d (22). Cultured cells con-
sisted of 
 
 
 
75% CD14
 
 
 
 CD83
 
 
 
 HLA-DR
 
 
 
 DCs, with contaminating cells
being B cells and dying myeloid cells. To generate mature DCs, cultures
were stimulated on day 6 with 50 ng/ml TNF-
 
 
 
 (Qbiogene) and 10 mM
PGE-2 (Sigma-Aldrich) for 36–48 h (23). At that time, cells were 
 
 
 
85%
CD14
 
 
 
 CD83
 
 
 
 HLA-DR
 
HI
 
 DCs. Patient material was obtained as per
protocol approved by the Institutional Review Board of the Rockefeller
University Hospital (JKR-0397), and all patients gave informed written
consent. Immunized donor 1 was vaccinated in 2000, and donor 2 was vac-
cinated in 2001. “Naive donor” refers to healthy blood donors that have
not received any flavivirus vaccine.
 
Preparation of virus stocks.
 
YF17D viral stocks were derived from
pACNR/FLYF plasmid containing the full-length infectious YF17D ge-
nome under an SP6 promoter (24). In vitro–generated RNA transcripts
were electroporated in SW13 cells as previously described (25). Virus stocks
were harvested at 48 h after transfection with typical yields of 10
 
7
 
–10
 
8
 
PFU/ml as determined by plaque assay on SW13. Single-use aliquots were
stored frozen at –80
 
 
 
C until use. YF17D/M1 was constructed by inserting
the influenza HLA-A2 CTL epitope of matrix protein (GILGFVFTL) (26)
between YF NS2B and NS3 proteins. Two specific oligonucleotides con-
taining the M1 epitope sequence (forward, 5
 
 
 
-aggggagcgcgcagaagtggaattt-
taggattcgtgttcacgctcggtcaccggagaagt-3
 
 
 
 and reverse, 5
 
 
 
-acttctccggtgac-
cgagcgtgaacacgaatcctaaaattccacttctgcgcgctcccct-3
 
 
 
) and two YF17D-specific
primers were used to generate two PCR fragments containing the influenza
M1 epitope and a portion of the NS2B or NS3 gene, respectively. 1/50 
 
 
 
l
of each PCR reaction was mixed together and used as a template for PCR
with YF17D-specific primers lying in NS2B and in NS3. The final product
was digested with BssHII and BstEII and cloned in YF17D2B/3 as de-
scribed previously (7). The recombinant virus was recovered 48 h after
transfection of SW13 cells with infectious RNA and tested for stability by
PCR and sequence analysis of the region overlapping the insertion. UV in-
activation was performed with a UV chamber (GS Gene-Linker; Bio-Rad
Laboratories) using the sterilizing program.
 
Infection of cells.
 
DCs were washed in RPMI 1640 and infected for 1 h
at 37
 
 
 
C using the PFUs indicated in the figures. UV-inactivated virus was
used as a negative control. The infection was quenched with 5% pooled hu-
man serum and washed twice to remove excess virus. For EDTA/EGTA
blocking, DCs were washed twice in PBS without Ca
 
2
 
 
 
 and Mg
 
2
 
 
 
, and 10
mM EDTA or EGTA was added before infection. For antibody blocking,
DCs were washed in RPMI 1640 and resuspended in 1% FBS/PBS. DCs
were incubated with 10 
 
 
 
g/ml of antibody (DC-SIGN [m612; R&D Sys-
tems] or 
 
 
 
v
 
 
 
3 [Chemicon]) or 100 
 
 
 
g/ml RGD tripeptides (Sigma-
Aldrich) for 15 min at room temperature before infection. After 1 h of in-
fection, DCs were resuspended in conditioned media with or without
TNF-
 
 
 
/PGE-2 maturation stimulus, as indicated in the figures, and incu-
bated 24 h before monitoring for infection.
 
Immunostaining for FACS analysis.
 
Surface staining was done in
serum containing media at 4
 
 
 
C. Anti-CD14, CD25, CD40, CD83,
CD86, HLA-DR, and isotype control were obtained from BD Bio-
sciences. Cytoperm/CytoFix Kit from BD Biosciences was used for fix-
ation and permeabilization. mAb 1A5 is a mouse mAb against the non-
structural protein NS1 (27), and C12 is a rabbit polyclonal antisera that
recognizes the nonstructural proteins NS4A and NS4B (28). Secondary
antibodies used were PE (Jackson ImmunoResearch Laboratories) or
APC (Invitrogen).
 
Plaque assay.
 
For plaque titration, serial 10-fold dilutions were used to
infect monolayers of SW13 for 1 h at 37
 
 
 
C. After infection, cells were over-
layed with 0.6% agarose-containing medium, and plaques were allowed to
develop at 37
 
 
 
C for 4 d. Plaques were fixed in 7% formaldehyde for 1 h and
stained with crystal violet (1.25% in 20% ETOH) (25).
 
Detection of influenza-specific T cells by ELISPOT.
 
DCs and T
cells were plated in 96-well Millipore plates coated with 5 
 
 
 
g/ml of
 
 
 
-IFN-
 
 
 
 mAb (Mab-1-D1K; Mabtech). Cultures were incubated for 24– 
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36 h at 37 C, washed with mild detergent, and incubated with 1  g/ml bio-
tin-conjugated  -IFN-  mAb (Mab 7BG-1; Mabtech). Spots were visual-
ized using Vectastain Elite Kit (Vector Laboratories). ELISPOT reagents
were provided by R. Darnell (The Rockefeller University, New York,
NY). Evaluation was performed in a blinded fashion by an independent ser-
vice (Zellnet Consulting, Inc.) using an automated ELISPOT reader (Carl
Zeiss MicroImaging, Inc.). Spots represent IFN-  production by single cells
and are reported as spot-forming cells/106 cells.
Online supplemental material. Fig. S1 shows purity and phenotype of
iDC and mDC cultures. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20051352/DC1.
We would like to thank R. Darnell for reagents and helpful suggestions.
This work was supported by the Greenberg Medical Research Institute and the 
Grand Challenges in Global Health. We are grateful to the donors who participated 
in this study.
The authors have no conflicting financial interests.
Submitted: 7 July 2005
Accepted: 16 September 2005
REFERENCES
1. World Health Organization. 2003. Yellow fever vaccine. WHO posi-
tion paper. Wkly. Epidemiol. Rec. 78:349–359.
2. Hahn, C.S., J.M. Dalrymple, J.H. Strauss, and C.M. Rice. 1987. Com-
parison of the virulent Asibi strain of yellow fever virus with the 17D
vaccine strain derived from it. Proc. Natl. Acad. Sci. USA. 84:2019–2023.
3. Poland, J.D., C.H. Calisher, T.P. Monath, W.G. Downs, and K. Mur-
phy. 1981. Persistence of neutralizing antibody 30-35 years after im-
munization with 17D yellow fever vaccine. Bull. World Health Organ.
59:895–900.
4. Reinhardt, B., R. Jaspert, M. Niedrig, C. Kostner, and J. L’Age-Stehr.
1998. Development of viremia and humoral and cellular parameters of
immune activation after vaccination with yellow fever virus strain 17D:
a model of human flavivirus infection. J. Med. Virol. 56:159–167.
5. Co, M.D., M. Terajima, J. Cruz, F.A. Ennis, and A.L. Rothman.
2002. Human cytotoxic T lymphocyte responses to live attenuated
17D yellow fever vaccine: identification of HLA-B35-restricted CTL
epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural
protein E. Virology. 293:151–163.
6. Monath, T.P., F. Guirakhoo, R. Nichols, S. Yoksan, R. Schrader, C.
Murphy, P. Blum, S. Woodward, K. McCarthy, D. Mathis, et al. 2003.
Chimeric live, attenuated vaccine against Japanese encephalitis (Chi-
meriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect
of vaccine dose and schedule, and memory response to challenge with
inactivated Japanese encephalitis antigen. J. Infect. Dis. 188:1213–1230.
7. Tao, D., G. Barba-Spaeth, U. Rai, V. Nussenzweig, C.M. Rice, and
R.S. Nussenzweig. 2005. Yellow fever 17D as a vaccine vector for mi-
crobial CTL epitopes: protection in a rodent malaria model. J. Exp.
Med. 201:201–209.
8. Banchereau, J., and R.M. Steinman. 1998. Dendritic cells and the con-
trol of immunity. Nature. 392:245–252.
9. Tassaneetrithep, B., T.H. Burgess, A. Granelli-Piperno, C. Trumpf-
heller, J. Finke, W. Sun, M.A. Eller, K. Pattanapanyasat, S. Sarasom-
bath, D.L. Birx, et al. 2003. DC-SIGN (CD209) mediates dengue vi-
rus infection of human dendritic cells. J. Exp. Med. 197:823–829.
10. Navarro-Sanchez, E., R. Altmeyer, A. Amara, O. Schwartz, F. Fieschi,
J.L. Virelizier, F. Arenzana-Seisdedos, and P. Despres. 2003. Den-
dritic-cell-specific ICAM3-grabbing non-integrin is essential for the
productive infection of human dendritic cells by mosquito-cell-derived
dengue viruses. EMBO Rep. 4:723–728.
11. Rehermann, B., and M. Nascimbeni. 2005. Immunology of hepatitis B
virus and hepatitis C virus infection. Nat. Rev. Immunol. 5:215–229.
12. Chu, J.J., and M.L. Ng. 2004. Interaction of West Nile virus with al-
pha v beta 3 integrin mediates virus entry into cells. J. Biol. Chem. 279:
54533–54541.
13. van der Most, R.G., J. Corver, and J.H. Strauss. 1999. Mutagenesis of
the RGD motif in the yellow fever virus 17D envelope protein. Virol-
ogy. 265:83–95.
14. Post, P.R., C.N. Santos, R. Carvalho, A.C. Cruz, C.M. Rice, and
R. Galler. 1992. Heterogeneity in envelope protein sequence and
N-linked glycosylation among yellow fever virus vaccine strains. Virol-
ogy. 188:160–167.
15. Cella, M., M. Salio, Y. Sakakibara, H. Langen, I. Julkunen, and A. Lan-
zavecchia. 1999. Maturation, activation, and protection of dendritic cells
induced by double-stranded RNA. J. Exp. Med. 189:821–829.
16. Fugier-Vivier, I., C. Servet-Delprat, P. Rivailler, M.C. Rissoan, Y.J.
Liu, and C. Rabourdin-Combe. 1997. Measles virus suppresses cell-
mediated immunity by interfering with the survival and functions of
dendritic and T cells. J. Exp. Med. 186:813–823.
17. Pollara, G., K. Speidel, L. Samady, M. Rajpopat, Y. McGrath, J. Le-
dermann, R.S. Coffin, D.R. Katz, and B. Chain. 2003. Herpes simplex
virus infection of dendritic cells: balance among activation, inhibition,
and immunity. J. Infect. Dis. 187:165–178.
18. Hacker, U.T., T. Jelinek, S. Erhardt, A. Eigler, G. Hartmann, H.D.
Nothdurft, and S. Endres. 1998. In vivo synthesis of tumor necrosis
factor-alpha in healthy humans after live yellow fever vaccination. J.
Infect. Dis. 177:774–778.
19. Paludan, C., D. Schmid, M. Landthaler, M. Vockerodt, D. Kube, T.
Tuschl, and C. Munz. 2005. Endogenous MHC class II processing of a
viral nuclear antigen after autophagy. Science. 307:593–596.
20. McAllister, A., A.E. Arbetman, S. Mandl, C. Pena-Rossi, and R. An-
dino. 2000. Recombinant yellow fever viruses are effective therapeutic
vaccines for treatment of murine experimental solid tumors and pul-
monary metastases. J. Virol. 74:9197–9205.
21. Bhardwaj, N., A. Bender, N. Gonzalez, L.K. Bui, M.C. Garrett, and
R.M. Steinman. 1994. Influenza virus-infected dendritic cells stimulate
strong proliferative and cytolytic responses from human CD8  T cells.
J. Clin. Invest. 94:797–807.
22. Romani, N., D. Reider, M. Heuer, S. Ebner, E. Kampgen, B. Eibl, D.
Niederwieser, and G. Schuler. 1996. Generation of mature dendritic
cells from human blood. An improved method with special regard to
clinical applicability. J. Immunol. Methods. 196:137–151.
23. Rieser, C., G. Bock, H. Klocker, G. Bartsch, and M. Thurnher. 1997.
Prostaglandin E2 and tumor necrosis factor–  cooperate to activate hu-
man dendritic cells: synergistic activation of interleukin-12 production.
J. Exp. Med. 186:1603–1608.
24. Bredenbeek, P.J., E.A. Kooi, B. Lindenbach, N. Huijkman, C.M.
Rice, and W.J. Spaan. 2003. A stable full-length yellow fever virus
cDNA clone and the role of conserved RNA elements in flavivirus
replication. J. Gen. Virol. 84:1261–1268.
25. Amberg, S.M., and C.M. Rice. 1999. Mutagenesis of the NS2B-NS3-
mediated cleavage site in the flavivirus capsid protein demonstrates a
requirement for coordinated processing. J. Virol. 73:8083–8094.
26. Gotch, F., J. Rothbard, K. Howland, A. Townsend, and A. Mc-
Michael. 1987. Cytotoxic T lymphocytes recognize a fragment of in-
fluenza virus matrix protein in association with HLA-A2. Nature. 326:
881–882.
27. Schlesinger, J.J., E.E. Walsh, and M.W. Brandriss. 1984. Analysis of
17D yellow fever virus envelope protein epitopes using monoclonal
antibodies. J. Gen. Virol. 65:1637–1644.
28. Chambers, T.J., D.W. McCourt, and C.M. Rice. 1989. Yellow fever
virus proteins NS2A, NS2B, and NS4B: identification and partial
N-terminal amino acid sequence analysis. Virology. 169:100–109.